Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04971226 · ClinicalTrials.gov registry record · Phase 3
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
A Phase 3 study of Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 406
- Enrollment target
- 20
- Study locations
NCT04971226 is a Phase 3 study of Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 406 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT04971226, a Phase 3 study of Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 406 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected Tyrosine Kinase Inhibitor (TKI) for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP. The Investigator selected TKI will be one of the following treatment options for first-line treatment of CML-CP - imatinib 400 mg QD or nilotinib 300 mg BID or dasatinib 100 mg QD or bosutinib 400 mg QD. This study has three periods: 1. Treatment period for all randomized participants, 2. Optional Treatment-Free Remission (TFR) period only for participants meeting TFR eligibility criteria and 3. Treatment Re-Initiation (TRI) period only for participants who relapsed after TFR attempt.
Conditions Studied
Interventions
- DRUG Dasatinib
- DRUG Bosutinib
- DRUG Nilotinib
- DRUG Imatinib
- DRUG Asciminib
Study Locations (20)
Texas
- Texas Oncology-Baylor USO - Dallas
- Texas Oncology - Dallas
- Texas Oncology - Dallas
Florida
- Florida Cancer Specialists - Fort Myers
- Florida Cancer Specialists Pan - Tallahassee
Oregon
- Williamette Cancer Center - Eugene
- Oregon Health Sciences University - Portland
New South Wales
- Novartis Investigative Site - Kingswood
- Novartis Investigative Site - Port Macquarie
Other
- Novartis Investigative Site - Southport
- Novartis Investigative Site - Brussels
Colorado
- Rocky Mountain Cancer Centers - Denver
Kentucky
- University of Kentucky - Lexington
Massachusetts
- Uni of Massachusetts Medical Center - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2031-01-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04971226
The ClinicalTrials.gov registry entry for NCT04971226 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive appearing as the primary indexed condition, and to 5 interventions - of which Dasatinib is the first listed.
NCT04971226 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Texas, Florida, Oregon.
Frequently Asked Questions
What is clinical trial NCT04971226 about?
NCT04971226 is a clinical study titled "A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP". The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected Tyrosine Kinase Inhibitor (TKI) for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP. The Investigator selected TKI will be one of the following treatment options for first...
What is the current status of trial NCT04971226?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 406 participants. The study started on 2021-10-06. Estimated completion is 2031-01-18.
What conditions does trial NCT04971226 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive.
What interventions are being tested in trial NCT04971226?
The interventions under investigation include: Dasatinib (DRUG), Bosutinib (DRUG), Nilotinib (DRUG), Imatinib (DRUG), Asciminib (DRUG).
Who is sponsoring clinical trial NCT04971226?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04971226 being conducted?
This trial has 20 study locations across Colorado, Florida, Kentucky, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.